DIVIS LABORATORIES LTD Q2 RESULTS
F&O outliers: September seasonality weighs on ICICI Bank, Adani Ports, TVS Motors, 7 others. Here's why
Over the last decade, five F&O stocks showed positive seasonality in September with average returns over 5%, including TVS Motor, Deepak Nitrite, Abbott India, Escorts Kubota, and Zee Entertainment. Conversely, ICICI Bank, APSEZ, SBI, Cummins India, and Dabur India had negative seasonality, with average losses of 2% or more.
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 36%
While it is always better to do it, there are some phases when it is important to de-link with what is happening to nifty and stocks in your portfolio. The reason, if one looks at the composition of the Nifty and Sensex, they can be impacted by movement in one or two sectors. At this point in time, while the overall market trend is bullish, the market is moving more into stock-specific mode, a sort of profit booking and that is why divergence between the value of the portfolio and what is happening to nifty might become a common thing. These selected stocks depict a strong upward trajectory in their overall average score which is based on five key pillars i.e. earnings, fundamentals, relative valuation, risk and price momentum. This implies that there has been a significant improvement in their market outlook in the given time frame.
Dr Reddy's Laboratories, TCS top stocks to buy post June quarter results: Siddhartha Khemka
The 1QFY25 corporate earnings report revealed both growth and challenges in India’s market. The Nifty50’s earnings rose 4% YoY, aided by companies like HDFC Bank and Tata Motors, despite setbacks from Oil Marketing Companies. The auto sector displayed strong volume growth, while IT services and healthcare sectors met expectations with promising future outlooks.
Ipca Labs Q1 Results: Net profit up 18% at Rs 192 crore
Revenue from operations rose to Rs 2,093 crore for the April-June quarter, as compared to Rs 1,585 crore in the year-ago period, Ipca Laboratories said in a regulatory filing.
Alkem Labs Q1 Results: Net profit zooms 90% to Rs 545 crore
The company reported Rs 287 crore in the corresponding quarter of the previous year. Revenue from operations grew 2.2% y-o-y to Rs 3032 crore in Q1FY25.
Q1 results, IPO action among 10 factors that will steer D-Street this week
The Street will react to major earnings reports from SBI, Divi’s Laboratories, Titan, and Britannia when markets resume trading on Monday. Additionally, 922 BSE-listed companies will announce April-June earnings, including Bharti Airtel and Tata Power. Indian markets will take cues from US market closures and GIFT Nifty futures.
- Go To Page 1
Divi's Laboratories Q1 Results: Cons PAT jumps 21% YoY to Rs 430 crore, misses estimates
Divi's Laboratories reported a consolidated net profit of Rs 430 crore for the quarter ended June 30, 2024, which was up by 21% over Rs 356 crore reported by the company in the year ago period. It was lower than Street's estimates of Rs 448 crore.
Q1 Results Today: SBI among 41 companies to announce earnings on Saturday
State Bank of India, India's largest public sector bank, is expected to report a slight decrease in profits for the first quarter of 2024 due to increased provisions, despite a projected 10% growth in net interest income.
Q1 results this week: ITC, SBI, TaMo, Zomato among 130 firms to announce earnings
This week, several prominent companies released their June quarter financial results. Firms like ITC, SBI, Adani Ports, Tata Motors, and M&M showcased their reports between July 29th and August 3rd. The updates offered a glimpse into their quarterly performance, engaging the attention of investors and stakeholders.
Q4 results: Stable costs boost India Inc. profits
Steady costs and firm domestic demand supported corporate performance in the March quarter.
F&O stocks: Hindustan Aeronautics, Birlasoft among 5 stocks with short buildup
Coming to the buildup of fresh short positions, When the stock prices move downward and open interest on the counter increases, it is taken as a sign of a short build-up. The signal is considered more reliable if the volume on the counter has also seen an increase as the stock price declines.
F&O stocks: Exide Industries, Divi's Laboratories among 5 stocks with long buildup
In Tuesday’s trading session, Exide Industries, Muthoot Finance, Jubilant FoodWorks, Divi's Laboratories, and Sun TV witnessed a build of fresh long positions with stock price and open interest increases.
Divi’s Laboratories shares rally 5% post Q4 results. Should you buy, sell or hold?
Divi’s Laboratories saw a 5% surge in its shares on the BSE during Monday's trading session, reaching a new 52-week high of Rs 4,335. This rise came as brokerages such as Motilal Oswal and InCred expressed bullish sentiment towards the stock, following the company's impressive performance in Q4, where it reported a 68% year-on-year increase in profits, reaching Rs 538 crore.
Hot Stocks: Brokerage view on Exide, Divi’s Laboratories, Ashok Leyland & Sun TV
Top brokerages have issued bullish recommendations for select stocks. CLSA has maintained an outperform rating on Sun TV, raising the target to Rs 720. InCred has upgraded Divi’s Laboratories to Add. Meanwhile, JPMorgan maintains an overweight rating on Exide Industries, with a target price of Rs 520.
Divi's Laboratories Q4 Results: Cons PAT soars 68% YoY to Rs 538 crore; dividend declared at Rs 30 per share
Divi's Laboratories Q4 Results: Net profit stood at Rs 321 crore in the corresponding quarter of the last financial year. The consolidated revenue in Q4 FY24 jumped 18% YoY to Rs 2,303 crore from Rs 1,951 crore reported in Q4 FY23. For the full financial year FY24, the consolidated profit after tax was reported at Rs 1,600 crore, a considerable drop from Rs 1,824 crore reported in FY23.
Q4 results this week: ITC, ONGC, Sun Pharma, Nykaa, Ircon International and IRFC
ITC, ONGC, IRFC, Ircon International, BHEL, BEL, Sun Pharma, Nykaa, Tata Investment Corporation, Hindalco, Ashok Leyland, and Divi's lab will be releasing their March quarter report cards this week.
Will Nifty hit fresh record high before elections? That depends on these 5 factors
The week may remain lacklustre on the data front as no major economic data releases are scheduled in both the US as well as the Indian market. Indian investors are likely to focus more on the ongoing earnings season as well as stock specific developments. Nifty and Sensex have reached all-time highs driven by US Fed data and expert insights. Key factors that will shape market outlook.
Dr Lal PathLabs Q4 Results: Net profit rises 51% YoY to Rs 86 crore on improved volumes of diagnostic tests
Dr Lal PathLabs on Friday reported a 51% year-on-year (YoY) jump in net profit to Rs 86 crore in the quarter ended March 2024 led by improved volumes of diagnostic tests.
Abbott India Q4 Results: Net profit rises 24% YoY on higher sales
Indian drugmaker Abbott India reported a 24% rise in fourth-quarter profit on Thursday, as strong sales outpaced the impact of government pricing caps on certain medicines.
Dr Reddy’s shares tumble 5% as Q4 numbers fail to impress analysts. Should you buy, sell or hold?
Dr Reddy’s Share Price: The company said that the jump in YoY net profit was largely driven by growth in global generics revenues in North America as well as emerging markets. DRL’s revenue also increased 12% YoY to Rs 7,083 crore.
Dr Reddy's Labs Q4 Results: PAT jumps 36% YoY to Rs 1,307 crore; firm declares dividend of Rs 40/share
Dr Reddy's Labs Q4 Results: The revenue from operations rose 12% YoY to Rs 7,083 crore while they dipped 2% quarter-on-quarter (QoQ). The revenue missed ET Now poll estimate of Rs 7,237 crore.
Dr Reddy's Q4 Preview: PAT may rise over 50% YoY on strong US sales
Based on an average estimate from four brokerages, revenue from operations during the January-March 2023 period is anticipated to increase by up to 18% year-on-year. Concurrently, the net profit after tax is expected to experience a robust surge of up to 54% year-on-year.
Motilal tweaks FY25 earnings outlook of Tata Motors, ITC and 8 other companies after Q3 show
The aggregate earnings of the companies in the MOFSL universe exceeded expectations and rose 29% year-on-year (YoY) versus an estimated 19%. Earnings for the Nifty-50 jumped 17% YoY versus an estimated 11%.
Divis Labs Q3 Results: Profit rises 17% YoY to Rs 358 crore
Revenue from operations in the reporting period increased 9% year-on-year to Rs 1,855 crore, compared with Rs 1708 crore in the corresponding period of last year.
Divi’s Labs Q3 results today: Could there be any fireworks in the scorecard?
The consolidated net profit for the quarter is seen rising 33% YoY to Rs 407.40 crore, according to the average of estimates given by five brokerage firms.
Q3 Results Today: Divi’s Lab, ONGC, MCX among 170 companies to announce earnings
Among other important results will be those by Aurobindo Pharma, Chemcon Speciality Chemicals, Sai Silks (Kalamandir), Mawana Sugars, MM Forgings and Yatharth Hospital & Trauma Care Services.
Divi’s Labs Q3 preview: PAT may grow 33% YoY on favourable base; outlook eyed
The consolidated net profit for the quarter is seen rising 33% YoY to Rs 407.40 crore, according to the average of estimates given by five brokerage firms.
Divi's Lab Q2 Results: Profit falls 29% YoY to Rs 348 crore, misses estimates
Revenue from operations rose 3% year-on-year (YoY) to Rs 1,909 crore in the July-September period. It was Rs 1,855 crore in the corresponding quarter of the previous year.
268 companies set to release Q2 results on Monday. What to expect from Nykaa, Divi’s Labs and Varun Beverages
Max Healthcare Institute, NHPC, Bharat Forge, Hindustan Petroleum Corporation, Gland Pharma, Emami, Exide Industries, R R Kabel, Bajaj Electricals, Bikaji Foods International, Sun Pharma Advanced Research, Sobha Ltd, Ujjivan Financial Services, Quess Corp, Fusion MicroFinance, Gateway Distriparks, Heidelberg Cement, Va Tech Wabag, and Paras Defence and Space Technologies are among the other major companies releasing results on Monday.
Load More